VIVOZON PHARMACEUTICAL (082800) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, VIVOZON PHARMACEUTICAL (082800) reported revenue of 59.3 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202559.3 billion KRW-19.2 billion KRW-32.4 billion KRW[source]
202487.6 billion KRW2.9 billion KRW-10.0 billion KRW[source]
202371.3 billion KRW2.6 billion KRW-3.4 billion KRW[source]
202259.1 billion KRW-18.5 billion KRW-39.2 billion KRW[source]
202157.7 billion KRW-17.9 billion KRW-71.0 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025177.3 billion KRW92.6 billion KRW84.7 billion KRW[source]
2024188.4 billion KRW77.9 billion KRW110.5 billion KRW[source]
2023180.4 billion KRW69.2 billion KRW111.2 billion KRW[source]
2022185.3 billion KRW79.4 billion KRW105.9 billion KRW[source]
2021141.5 billion KRW59.4 billion KRW82.1 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice